{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:58:49Z","timestamp":1778263129603,"version":"3.51.4"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.phrs.2019.03.014","type":"journal-article","created":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T18:48:10Z","timestamp":1553021290000},"page":"86-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Expanding spectrum of anticancer drug, imatinib, in the disorders affecting brain and spinal cord"],"prefix":"10.1016","volume":"143","author":[{"given":"Manish","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritu","family":"Kulshrestha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirmal","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amteshwar Singh","family":"Jaggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"September (6)","key":"10.1016\/j.phrs.2019.03.014_bib0005","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.phrs.2019.03.014_bib0010","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1517\/14740338.2016.1152258","article-title":"A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor","volume":"15","author":"Ben Ami","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"issue":"February (9)","key":"10.1016\/j.phrs.2019.03.014_bib0015","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra013339","article-title":"Imatinib mesylate--a new oral targeted therapy","volume":"346","author":"Savage","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.03.014_bib0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-642-01222-8_1","article-title":"Imatinib mesylate","volume":"184","author":"Waller","year":"2010","journal-title":"Recent Results Cancer Res."},{"issue":"April (14)","key":"10.1016\/j.phrs.2019.03.014_bib0025","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.phrs.2019.03.014_bib0030","doi-asserted-by":"crossref","first-page":"101","DOI":"10.7150\/ijms.1.101","article-title":"Tyrosine kinase - Role and significance in Cancer","volume":"1","author":"Paul","year":"2004","journal-title":"Int. J. Med. Sci."},{"issue":"May (5)","key":"10.1016\/j.phrs.2019.03.014_bib0035","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1111\/j.1471-4159.1988.tb03029.x","article-title":"Protein tyrosine kinase activity and its endogenous substrates in rat brain: a subcellular and regional survey","volume":"50","author":"Hirano","year":"1988","journal-title":"J. Neurochem."},{"issue":"March (3)","key":"10.1016\/j.phrs.2019.03.014_bib0040","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s12026-015-8624-6","article-title":"c-kit plays a critical role in induction of intravenous tolerance in experimental autoimmune encephalomyelitis","volume":"61","author":"Safavi","year":"2015","journal-title":"Immunol. Res."},{"issue":"August (9)","key":"10.1016\/j.phrs.2019.03.014_bib0045","first-page":"5505","article-title":"Intranasal sirna targeting c-kit reduces airway inflammation in experimental allergic asthma","volume":"7","author":"Wu","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"July (7)","key":"10.1016\/j.phrs.2019.03.014_bib0050","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nm1787","article-title":"Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke","volume":"14","author":"Su","year":"2008","journal-title":"Nat. Med."},{"issue":"December (6)","key":"10.1016\/j.phrs.2019.03.014_bib0055","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/ana.22549","article-title":"PDGFR-\u03b1 inhibition preserves blood-brain barrier after intracerebral hemorrhage","volume":"70","author":"Ma","year":"2011","journal-title":"Ann. Neurol."},{"issue":"January (1)","key":"10.1016\/j.phrs.2019.03.014_bib0060","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/jnr.23475","article-title":"Imatinib preserves blood-brain barrier integrity following experimental subarachnoid hemorrhage in rats","volume":"93","author":"Zhan","year":"2015","journal-title":"J. Neurosci. Res."},{"issue":"2","key":"10.1016\/j.phrs.2019.03.014_bib0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056586","article-title":"Imatinib ameliorates neuroinflammation in a rat model of multiple sclerosis by enhancing blood-brain barrier integrity and by modulating the peripheral immune response","volume":"8","author":"Adzemovic","year":"2013","journal-title":"PLoS One"},{"issue":"March (3)","key":"10.1016\/j.phrs.2019.03.014_bib0070","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/cdd.2015.135","article-title":"c-Abl\u2013p38\u03b1 signaling plays an important role in MPTP-induced neuronal death","volume":"23","author":"Wu","year":"2016","journal-title":"Cell Death Differ."},{"issue":"July (7)","key":"10.1016\/j.phrs.2019.03.014_bib0075","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.neurobiolaging.2009.07.007","article-title":"c-Abl tyrosine kinase modulates tau pathology and Cdk5 phosphorylation in AD transgenic mice","volume":"32","author":"Cancino","year":"2011","journal-title":"Neurobiol. Aging"},{"issue":"December 5","key":"10.1016\/j.phrs.2019.03.014_bib0080","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1750-1326-5-58","article-title":"Huntingtin cleavage product A forms in neurons and is reduced by gamma-secretase inhibitors","volume":"14","author":"Kegel","year":"2010","journal-title":"Mol. Neurodegener."},{"issue":"6","key":"10.1016\/j.phrs.2019.03.014_bib0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038760","article-title":"Imatinib enhances functional outcome after spinal cord injury","volume":"7","author":"Abrams","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2019.03.014_bib0090","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/978-94-007-5416-4_14","article-title":"Alzheimer\u2019s disease","volume":"65","author":"De-Paula","year":"2012","journal-title":"Subcell. Biochem."},{"issue":"July-August (4)","key":"10.1016\/j.phrs.2019.03.014_bib0095","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/msj.20279","article-title":"Alzheimer\u2019s disease: diagnosis and treatment across the spectrum of disease severity","volume":"78","author":"Neugroschl","year":"2011","journal-title":"Mt. Sinai J. Med."},{"issue":"April (2)","key":"10.1016\/j.phrs.2019.03.014_bib0100","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/CON.0000000000000307","article-title":"Alzheimer\u2019s disease","volume":"22","author":"Apostolova","year":"2016","journal-title":"Continuum (Minneap Minn)"},{"issue":"September (4)","key":"10.1016\/j.phrs.2019.03.014_bib0105","doi-asserted-by":"crossref","first-page":"553","DOI":"10.33549\/physiolres.933480","article-title":"Lipopolysaccharide-induced memory impairment in rats: a model of Alzheimer\u2019s disease","volume":"66","author":"Zakaria","year":"2017","journal-title":"Physiol. Res."},{"issue":"October","key":"10.1016\/j.phrs.2019.03.014_bib0110","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bbi.2013.05.002","article-title":"Imatinib methanesulfonate reduces hippocampal amyloid-\u03b2 and restores cognitive function following repeated endotoxin exposure","volume":"33","author":"Weintraub","year":"2013","journal-title":"Brain Behav. Immun."},{"issue":"September 331","key":"10.1016\/j.phrs.2019.03.014_bib0115","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neuroscience.2016.06.007","article-title":"Imatinib methanesulfonate reduces hyperphosphorylation of tau following repeated peripheral exposure to lipopolysaccharide","volume":"7","author":"Gardner","year":"2016","journal-title":"Neuroscience"},{"issue":"April (1)","key":"10.1016\/j.phrs.2019.03.014_bib0120","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.bbr.2012.01.010","article-title":"Prolonged elevation in hippocampal A\u03b2 and cognitive deficits following repeated endotoxin exposure in the mouse","volume":"229","author":"Kahn","year":"2012","journal-title":"Behav. Brain Res."},{"issue":"August 5","key":"10.1016\/j.phrs.2019.03.014_bib0125","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1742-2094-5-37","article-title":"Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation","volume":"29","author":"Lee","year":"2008","journal-title":"J. Neuroinflammation"},{"issue":"September (39)","key":"10.1016\/j.phrs.2019.03.014_bib0130","doi-asserted-by":"crossref","first-page":"8843","DOI":"10.1523\/JNEUROSCI.2868-05.2005","article-title":"Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer\u2019s disease","volume":"25","author":"Kitazawa","year":"2005","journal-title":"J. Neurosci."},{"issue":"October (1)","key":"10.1016\/j.phrs.2019.03.014_bib0135","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1046\/j.1365-2141.2002.03881.x","article-title":"Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid","volume":"119","author":"Takayama","year":"2002","journal-title":"Br. J. Haematol."},{"issue":"June (12)","key":"10.1016\/j.phrs.2019.03.014_bib0140","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1182\/blood-2002-10-3059","article-title":"The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr\/Abl-induced leukemia","volume":"101","author":"Wolff","year":"2003","journal-title":"Blood"},{"issue":"June (6)","key":"10.1016\/j.phrs.2019.03.014_bib0145","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/jnr.22603","article-title":"Peripheral reduction of \u03b2-amyloid is sufficient to reduce brain \u03b2-amyloid: implications for Alzheimer\u2019s disease","volume":"89","author":"Sutcliffe","year":"2011","journal-title":"J. Neurosci. Res."},{"issue":"September (Pt 9)","key":"10.1016\/j.phrs.2019.03.014_bib0150","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/brain\/awn125","article-title":"STI571 prevents apoptosis, tau phosphorylation and behavioural impairments induced by Alzheimer\u2019s beta-amyloid deposits","volume":"131","author":"Cancino","year":"2008","journal-title":"Brain"},{"issue":"October (3)","key":"10.1016\/j.phrs.2019.03.014_bib0155","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.3233\/JAD-151087","article-title":"Reduction of blood Amyloid-\u03b2 oligomers in Alzheimer\u2019s disease transgenic mice by c-Abl kinase inhibition","volume":"54","author":"Estrada","year":"2016","journal-title":"J. Alzheimers Dis."},{"issue":"July (3)","key":"10.1016\/j.phrs.2019.03.014_bib0160","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0896-6273(03)00434-3","article-title":"Triple-transgenic model of Alzheimer\u2019s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction","volume":"39","author":"Oddo","year":"2003","journal-title":"Neuron"},{"issue":"September (7311)","key":"10.1016\/j.phrs.2019.03.014_bib0165","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nature09325","article-title":"Gamma-secretase activating protein is a therapeutic target for Alzheimer\u2019s disease","volume":"467","author":"He","year":"2010","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.phrs.2019.03.014_bib0170","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3233\/JAD-140105","article-title":"Pharmacological modulation of GSAP reduces amyloid-\u03b2 levels and tau phosphorylation in a mouse model of Alzheimer\u2019s disease with plaques and tangles","volume":"41","author":"Chu","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.phrs.2019.03.014_bib0175","author":"Alzforum"},{"issue":"October (5 Suppl)","key":"10.1016\/j.phrs.2019.03.014_bib0180","first-page":"S374","article-title":"Imatinib treatment and A\u03b242 in humans","volume":"10","author":"Olsson","year":"2014","journal-title":"Alzheimers Dement."},{"issue":"November 9","key":"10.1016\/j.phrs.2019.03.014_bib0185","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1750-1326-9-48","article-title":"Oligomeric A\u03b2-induced synaptic dysfunction in Alzheimer\u2019s\u2019s disease","volume":"14","author":"Tu","year":"2014","journal-title":"Mol. Neurodegener."},{"issue":"Novemer (1)","key":"10.1016\/j.phrs.2019.03.014_bib0190","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s40478-018-0634-x","article-title":"In vivo induction of membrane damage by \u03b2-amyloid peptide oligomers","volume":"6","author":"Julien","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"issue":"November 20","key":"10.1016\/j.phrs.2019.03.014_bib0195","article-title":"Intracerebroventricular injection of resveratrol ameliorated A\u03b2-induced learning and cognitive decline in mice","author":"Qi","year":"2018","journal-title":"Metab. Brain Dis."},{"issue":"November (2)","key":"10.1016\/j.phrs.2019.03.014_bib0200","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.nbd.2004.06.007","article-title":"Activation of the neuronal c-Abl tyrosine kinase by amyloid-beta-peptide and reactive oxygen species","volume":"17","author":"Alvarez","year":"2004","journal-title":"Neurobiol. Dis."},{"issue":"October (21)","key":"10.1016\/j.phrs.2019.03.014_bib0205","doi-asserted-by":"crossref","first-page":"12444","DOI":"10.1073\/pnas.1534745100","article-title":"Gleevec inhibits beta-amyloid production but not Notch cleavage","volume":"100","author":"Netzer","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"February (6)","key":"10.1016\/j.phrs.2019.03.014_bib0210","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1073\/pnas.1620963114","article-title":"Gleevec shifts APP processing from a \u03b2-cleavage to a nonamyloidogenic cleavage","volume":"114","author":"Netzer","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"January (4)","key":"10.1016\/j.phrs.2019.03.014_bib0215","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1074\/jbc.M112.370924","article-title":"The role of \u03b3-secretase activating protein (GSAP) and imatinib in the regulation of \u03b3-secretase activity and amyloid-\u03b2 generation","volume":"288","author":"Hussain","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"September (9)","key":"10.1016\/j.phrs.2019.03.014_bib0220","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1091\/mbc.e07-01-0035","article-title":"Gleevec increases levels of the amyloid precursor protein intracellular domain and of the amyloid-beta degrading enzyme neprilysin","volume":"18","author":"Eisele","year":"2007","journal-title":"Mol. Biol. Cell"},{"issue":"November (3-4)","key":"10.1016\/j.phrs.2019.03.014_bib0225","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3233\/JAD-2000-23-408","article-title":"Generation of an apoptotic intracellular peptide by gamma-secretase cleavage of Alzheimer\u2019s amyloid beta protein precursor","volume":"2","author":"Passer","year":"2000","journal-title":"J. Alzheimers Dis."},{"issue":"April (1)","key":"10.1016\/j.phrs.2019.03.014_bib0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1471-4159.2002.00855.x","article-title":"Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases?","volume":"81","author":"Carson","year":"2002","journal-title":"J. Neurochem."},{"issue":"January (1)","key":"10.1016\/j.phrs.2019.03.014_bib0235","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ajpath.2010.11.012","article-title":"Neprilysin-2 is an important \u03b2-amyloid degrading enzyme","volume":"178","author":"Hafez","year":"2011","journal-title":"Am. J. Pathol."},{"issue":"May (4)","key":"10.1016\/j.phrs.2019.03.014_bib0240","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.neuron.2005.04.008","article-title":"Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP","volume":"46","author":"Pardossi-Piquard","year":"2005","journal-title":"Neuron"},{"issue":"July (5527)","key":"10.1016\/j.phrs.2019.03.014_bib0245","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1126\/science.1058783","article-title":"A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60","volume":"293","author":"Cao","year":"2001","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.phrs.2019.03.014_bib0250","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3233\/JAD-2011-110746","article-title":"\u03b3-Secretase-mediated regulation of neprilysin: influence of cell density and aging and modulation by imatinib","volume":"27","author":"Bauer","year":"2011","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.phrs.2019.03.014_bib0255","first-page":"113","article-title":"Cerebrovascular disease in the community: results of a WHO collaborative study","volume":"58","author":"Aho","year":"1980","journal-title":"Bull. World Health Organ."},{"issue":"September (3)","key":"10.1016\/j.phrs.2019.03.014_bib0260","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/ewjm.173.3.209","article-title":"Acute stroke","volume":"173","author":"Bath","year":"2000","journal-title":"West. J. Med."},{"issue":"7","key":"10.1016\/j.phrs.2019.03.014_bib0265","first-page":"200","article-title":"Stroke: classification and diagnosis","volume":"3","author":"Parmar","year":"2011","journal-title":"Clin. Pharm."},{"issue":"February (1)","key":"10.1016\/j.phrs.2019.03.014_bib0270","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s12975-014-0358-6","article-title":"Longitudinal assessment of imatinib\u2019s effect on the blood-brain barrier after ischemia\/reperfusion injury with permeability MRI","volume":"6","author":"Merali","year":"2015","journal-title":"Transl. Stroke Res."},{"issue":"9","key":"10.1016\/j.phrs.2019.03.014_bib0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024831","article-title":"Effects of Imatinib Mesylate (Gleevec) on human islet NF-kappaB activation and chemokine production in vitro","volume":"6","author":"Mokhtari","year":"2011","journal-title":"PLoS One"},{"issue":"June (6)","key":"10.1016\/j.phrs.2019.03.014_bib0280","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1002\/jcp.23029","article-title":"Imatinib treatment inhibit IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients","volume":"227","author":"Ciarcia","year":"2012","journal-title":"J. Cell. Physiol."},{"issue":"January (1)","key":"10.1016\/j.phrs.2019.03.014_bib0285","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1172\/JCI11830","article-title":"NF-kB: a key role in inflammatory diseases","volume":"107","author":"Tak","year":"2001","journal-title":"J. Clin. Invest."},{"issue":"January (11)","key":"10.1016\/j.phrs.2019.03.014_bib0290","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.3748\/wjg.v21.i11.3174","article-title":"Nuclear factor kappa B role in inflammation associated gastrointestinal malignancies","volume":"21","author":"Gambhir","year":"2015","journal-title":"World J. Gastroenterol."},{"issue":"November 1298","key":"10.1016\/j.phrs.2019.03.014_bib0295","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.brainres.2009.08.076","article-title":"Modulation of blood-brain barrier permeability by neutrophils: in vitro and in vivo studies","volume":"17","author":"Joice","year":"2009","journal-title":"Brain Res."},{"issue":"5","key":"10.1016\/j.phrs.2019.03.014_bib0300","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1159\/000343302","article-title":"C-reactive protein increases BBB permeability: implications for obesity and neuroinflammation","volume":"30","author":"Hsuchou","year":"2012","journal-title":"Cell. Physiol. Biochem."},{"issue":"March (3)","key":"10.1016\/j.phrs.2019.03.014_bib0305","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/joim.12576","article-title":"Randomized assessment of imatinib in patients with acute ischaemic stroke treated with intravenous thrombolysis","volume":"281","author":"Wahlgren","year":"2017","journal-title":"J. Intern. Med."},{"issue":"May 1565","key":"10.1016\/j.phrs.2019.03.014_bib0310","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.brainres.2014.03.027","article-title":"t-PA, but not desmoteplase, induces plasmin-dependent opening of a blood-brain barrier model under normoxic and ischaemic conditions","volume":"27","author":"Freeman","year":"2014","journal-title":"Brain Res."},{"issue":"October (4)","key":"10.1016\/j.phrs.2019.03.014_bib0315","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00401-017-1749-z","article-title":"Microglial-mediated PDGF-CC activation increases cerebrovascular permeability during ischemic stroke","volume":"134","author":"Su","year":"2017","journal-title":"Acta Neuropathol."},{"issue":"5","key":"10.1016\/j.phrs.2019.03.014_bib0320","first-page":"701","article-title":"Management of intracerebral hemorrhage","volume":"3","author":"Sahni","year":"2007","journal-title":"Vasc. Health Risk Manag."},{"issue":"May (9675)","key":"10.1016\/j.phrs.2019.03.014_bib0325","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/S0140-6736(09)60371-8","article-title":"Intracerebral haemorrhage","volume":"373","author":"Qureshi","year":"2009","journal-title":"Lancet"},{"issue":"September (9)","key":"10.1016\/j.phrs.2019.03.014_bib0330","first-page":"2203","article-title":"The role of platelet-derived growth factor receptor in early brain injury following subarachnoid hemorrhage","volume":"25","author":"Changlong","year":"2016","journal-title":"J. Stroke Cerebrovasc. Dis."},{"issue":"October 9","key":"10.1016\/j.phrs.2019.03.014_bib0335","first-page":"385","article-title":"Imatinib treatment reduces brain injury in a murine model of traumatic brain injury","volume":"7","author":"Su","year":"2015","journal-title":"Front. Cell. Neurosci."},{"issue":"April (1)","key":"10.1016\/j.phrs.2019.03.014_bib0340","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.nbd.2012.01.005","article-title":"Imatinib mesylate prevents cerebral vasospasm after subarachnoid hemorrhage via inhibiting tenascin-C expression in rats","volume":"46","author":"Shiba","year":"2012","journal-title":"Neurobiol. Dis."},{"issue":"April (2)","key":"10.1016\/j.phrs.2019.03.014_bib0345","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s12975-014-0333-2","article-title":"Tenascin-C causes neuronal apoptosis after subarachnoid hemorrhage in rats","volume":"5","author":"Shiba","year":"2014","journal-title":"Transl. Stroke Res."},{"issue":"October (4)","key":"10.1016\/j.phrs.2019.03.014_bib0350","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s12291-013-0387-z","article-title":"Induction of multiple sclerosis and response to tyrosine kinase inhibitors","volume":"29","author":"Moawad","year":"2014","journal-title":"Indian J. Clin. Biochem."},{"issue":"June (3)","key":"10.1016\/j.phrs.2019.03.014_bib0355","first-page":"198","article-title":"Effects of imatinib mesylate in mouse models of multiple sclerosis and in vitro determinants","volume":"13","author":"Azizi","year":"2014","journal-title":"Iran. J. Allergy Asthma Immunol."},{"issue":"January (Pt 1)","key":"10.1016\/j.phrs.2019.03.014_bib0360","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/brain\/awh655","article-title":"Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis","volume":"129","author":"Mahad","year":"2006","journal-title":"Brain"},{"issue":"December (6)","key":"10.1016\/j.phrs.2019.03.014_bib0365","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1007\/s10875-011-9579-6","article-title":"Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis","volume":"31","author":"Crespo","year":"2011","journal-title":"J. Clin. Immunol."},{"issue":"June (2)","key":"10.1016\/j.phrs.2019.03.014_bib0370","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11481-018-9783-8","article-title":"A role for the non-receptor tyrosine kinase Abl2\/Arg in experimental neuroinflammation","volume":"13","author":"Jacobsen","year":"2018","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.phrs.2019.03.014_bib0375","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1172\/JCI29178","article-title":"Diagnosis and treatment of Parkinson disease: molecules to medicine","volume":"116","author":"Savitt","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"July 11","key":"10.1016\/j.phrs.2019.03.014_bib0380","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1017\/S1462399409001148","article-title":"Molecular pathogenesis of Parkinson disease: insights from genetic studies","volume":"27","author":"Gasser","year":"2009","journal-title":"Expert Rev. Mol. Med."},{"issue":"April (7)","key":"10.1016\/j.phrs.2019.03.014_bib0385","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/j.1742-4658.2012.08491.x","article-title":"Animal models of Parkinson\u2019s disease","volume":"279","author":"Blandini","year":"2012","journal-title":"FEBS J."},{"issue":"March (1)","key":"10.1016\/j.phrs.2019.03.014_bib0390","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.molbrainres.2005.01.012","article-title":"Absence of inclusion body formation in the MPTP mouse model of Parkinson\u2019s disease","volume":"134","author":"Shimoji","year":"2005","journal-title":"Brain Res. Mol. Brain Res."},{"issue":"January (1","key":"10.1016\/j.phrs.2019.03.014_bib0395","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/sj.cr.7290257","article-title":"Activation and signaling of the p38 MAP kinase pathway","volume":"15","author":"Zarubin","year":"2005","journal-title":"Cell Res."},{"issue":"August (3)","key":"10.1016\/j.phrs.2019.03.014_bib0400","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1042\/BJ20100323","article-title":"Mechanisms and functions of p38 MAPK signalling","volume":"429","author":"Cuadrado","year":"2010","journal-title":"Biochem. J."},{"issue":"April 23","key":"10.1016\/j.phrs.2019.03.014_bib0405","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.12659\/MSM.900218","article-title":"MicroRNA-181a regulates apoptosis and autophagy process in parkinson\u2019s disease by inhibiting p38 mitogen-activated protein kinase (MAPK)\/c-Jun N-Terminal kinases (JNK) signaling pathways","volume":"2","author":"Liu","year":"2017","journal-title":"Med. Sci. Monit."},{"issue":"September (39)","key":"10.1016\/j.phrs.2019.03.014_bib0410","doi-asserted-by":"crossref","first-page":"23775","DOI":"10.1074\/jbc.271.39.23775","article-title":"Activation of p38 mitogen-activated protein kinase by c-Abl-dependent and -independent mechanisms","volume":"271","author":"Pandey","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"April (Pt 1)","key":"10.1016\/j.phrs.2019.03.014_bib0415","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1042\/BJ20040927","article-title":"Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr\/Abl: implications in the cellular response to Ara-C","volume":"387","author":"Sanchez-Ar\u00e9valo Lobo","year":"2005","journal-title":"Biochem. J."},{"issue":"January (2)","key":"10.1016\/j.phrs.2019.03.014_bib0420","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/ijc.23063","article-title":"c-Abl activates p38 MAPK independently of its tyrosine kinase activity: Implications in cisplatin-based therapy","volume":"122","author":"Galan-Moya","year":"2008","journal-title":"Int. J. Cancer"},{"issue":"May (9)","key":"10.1016\/j.phrs.2019.03.014_bib0425","first-page":"2464","article-title":"A role for the p38 mitogen-acitvated protein kinase pathway in the transcriptional activation of p53 on genotoxic stress by chemotherapeutic agents","volume":"60","author":"Sanchez-Prieto","year":"2000","journal-title":"Cancer Res."},{"issue":"April (1)","key":"10.1016\/j.phrs.2019.03.014_bib0430","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/ng0492-45","article-title":"Definition of a consensus binding site for p53","volume":"1","author":"El-Deiry","year":"1992","journal-title":"Nat. Genet."},{"issue":"July (4)","key":"10.1016\/j.phrs.2019.03.014_bib0435","doi-asserted-by":"crossref","first-page":"506","DOI":"10.14336\/AD.2016.1120","article-title":"P53 Dysfunction in Neurodegenerative Diseases - The Cause or Effect of Pathological Changes?","volume":"8","author":"Szybinska","year":"2017","journal-title":"Aging Dis."},{"issue":"November (47)","key":"10.1016\/j.phrs.2019.03.014_bib0440","doi-asserted-by":"crossref","first-page":"12500","DOI":"10.1523\/JNEUROSCI.4511-08.2008","article-title":"Selective activation of p38 mitogen-activated protein kinase in dopaminergic neurons of substantia nigra leads to nuclear translocation of p53 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice","volume":"28","author":"Karunakaran","year":"2008","journal-title":"J. Neurosci."},{"issue":"September (3)","key":"10.1016\/j.phrs.2019.03.014_bib0445","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.neuint.2013.05.006","article-title":"p38(MAPK)\/p53-Mediated Bax induction contributes to neurons degeneration in rotenone-induced cellular and rat models of Parkinson\u2019s disease","volume":"63","author":"Wu","year":"2013","journal-title":"Neurochem. Int."},{"issue":"December (6)","key":"10.1016\/j.phrs.2019.03.014_bib0450","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00401-017-1755-1","article-title":"Alpha-synuclein oligomers: a new hope","volume":"134","author":"Bengoa-Vergniory","year":"2017","journal-title":"Acta Neuropathol."},{"issue":"December (52)","key":"10.1016\/j.phrs.2019.03.014_bib0455","doi-asserted-by":"crossref","first-page":"50980","DOI":"10.1074\/jbc.M207825200","article-title":"Alpha-synuclein lowers p53-dependent apoptotic response of neuronal cells","volume":"277","author":"Alves Da Costa","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"April (14)","key":"10.1016\/j.phrs.2019.03.014_bib0460","doi-asserted-by":"crossref","first-page":"9824","DOI":"10.1074\/jbc.M513903200","article-title":"6-Hydroxydopamine but not 1-methyl-4-phenylpyridinium abolishes alpha-synuclein anti-apoptotic phenotype by inhibiting its proteasomal degradation and by promoting its aggregation","volume":"281","author":"Alves da Costa","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"July (6)","key":"10.1016\/j.phrs.2019.03.014_bib0465","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/BSD.0000000000000287","article-title":"Acute spinal cord injury","volume":"28","author":"Witiw","year":"2015","journal-title":"J. Spinal Disord. Tech."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818321054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818321054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:58:05Z","timestamp":1760911085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661818321054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":93,"alternative-id":["S1043661818321054"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.03.014","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expanding spectrum of anticancer drug, imatinib, in the disorders affecting brain and spinal cord","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}